In conclusion, the study findings suggest that cisplatin-induced cytotoxicity is mediated by the uptake of cisplatin by cancer cells through SLC22A3, and SLC22A3 expression in cancer cells is a potential biomarker for including cisplatin in cancer chemotherapy. The gene discussed is SLC22A3; the disease is cancer.